drugset / Trial / NCT06717815
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
Non-randomizedSequentialOpen-labelTreatment
Summary
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis
Timeline
- Start
- 2025-02-25
- Primary completion
- 2026-04-22
- Completion
- 2026-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPG11406 | Unknown | 20 mg | Oral |
| Subject | IPG11406 | Unknown | 40 mg | Oral |
| Subject | IPG11406 | Unknown | 80 mg | Oral |